Literature DB >> 24142483

The potential role of genetically-modified pig mesenchymal stromal cells in xenotransplantation.

Jiang Li1, Mohamed B Ezzelarab, David Ayares, David K C Cooper.   

Abstract

Mesenchymal stromal cells (MSCs) are known to have regenerative, anti-inflammatory, and immunodulatory effects. There are extensive indications that pig MSCs function satisfactorily across species barriers. Pig MSCs might have considerable therapeutic potential, particularly in xenotransplantation, where they have several potential advantages. (i) pMSCs can be obtained from the specific organ- or cell-source donor pig or from an identical (cloned) pig. (ii) They are easy to obtain in large numbers, negating the need for prolonged ex vivo expansion. (iii) They can be obtained from genetically-engineered pigs, and the genetic modification can be related to the therapeutic goal of the MSCs. We have reviewed our own studies on MSCs from genetically-engineered pigs, and summarize them here. We have successfully harvested and cultured MSCs from wild-type and genetically-engineered pig bone marrow and adipose tissue. We have identified several pig (p)MSC surface markers (positive for CD29, CD44, CD73, CD105, CD166, and negative for CD31, CD45), have demonstrated their proliferation and differentiation (into adipocytes, osteoblasts, and chondroblasts), and evaluated their antigenicity and immune suppressive effects on human peripheral blood mononuclear cells and CD4(+)T cells. They have identical or very similar characteristics to MSCs from other mammals. Genetically-modified pMSCs are significantly less immunogenic than wild-type pMSCs, and downregulate the human T cell response to pig antigens as efficiently as do human MSCs. We hypothesized that pMSCs can immunomodulate human T cells through induction of apoptosis or anergy, or cause T cell phenotype switching with induction of regulatory T cells, but we could find no evidence for these mechanisms. However, pMSCs upregulated the expression of CD69 on human CD4(+) and CD8(+) T cells, the relevance of which is currently under investigation. We conclude that MSCs from genetically-engineered pigs should continue to be investigated for their immunomodulatory (and regenerative and anti-inflammatory) effects in pig-to-nonhuman primate organ and cell transplantation models.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24142483      PMCID: PMC3946698          DOI: 10.1007/s12015-013-9478-8

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  25 in total

1.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

2.  Mesenchymal stem cell homing capacity.

Authors:  Valeria Sordi
Journal:  Transplantation       Date:  2009-05-15       Impact factor: 4.939

3.  Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia.

Authors:  Mario G Solari; Suganya Srinivasan; Imene Boumaza; Jignesh Unadkat; George Harb; Adolfo Garcia-Ocana; Maryam Feili-Hariri
Journal:  J Autoimmun       Date:  2009-02-12       Impact factor: 7.094

Review 4.  Mesenchymal stem cells in health and disease.

Authors:  Antonio Uccelli; Lorenzo Moretta; Vito Pistoia
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

5.  The potential of genetically-modified pig mesenchymal stromal cells in xenotransplantation.

Authors:  Mohamed Ezzelarab; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2010 Jan-Feb       Impact factor: 3.907

6.  Genetically-modified pig mesenchymal stromal cells: xenoantigenicity and effect on human T-cell xenoresponses.

Authors:  Mohamed Ezzelarab; Corin Ezzelarab; Tyler Wilhite; Goutham Kumar; Hidetaka Hara; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2011 May-Jun       Impact factor: 3.907

7.  Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.

Authors:  Norberto Perico; Federica Casiraghi; Martino Introna; Eliana Gotti; Marta Todeschini; Regiane Aparecida Cavinato; Chiara Capelli; Alessandro Rambaldi; Paola Cassis; Paola Rizzo; Monica Cortinovis; Maddalena Marasà; Josee Golay; Marina Noris; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-07       Impact factor: 8.237

8.  Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation.

Authors:  Gro Vatne Røsland; Agnete Svendsen; Anja Torsvik; Ewa Sobala; Emmet McCormack; Heike Immervoll; Josef Mysliwietz; Joerg-Christian Tonn; Roland Goldbrunner; Per Eystein Lønning; Rolf Bjerkvig; Christian Schichor
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

9.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Authors:  Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

10.  Mesenchymal stem cells: a potential border patrol for transplanted islets?

Authors:  Todd M Brusko
Journal:  Diabetes       Date:  2009-08       Impact factor: 9.461

View more
  9 in total

Review 1.  Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future.

Authors:  Zhengzhao Liu; Wenbao Hu; Tian He; Yifan Dai; Hidetaka Hara; Rita Bottino; David K C Cooper; Zhiming Cai; Lisha Mou
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

Review 2.  Functional augmentation of naturally-derived materials for tissue regeneration.

Authors:  Ashley B Allen; Lauren B Priddy; Mon-Tzu A Li; Robert E Guldberg
Journal:  Ann Biomed Eng       Date:  2014-11-25       Impact factor: 3.934

Review 3.  Pig Liver Xenotransplantation: A Review of Progress Toward the Clinic.

Authors:  David K C Cooper; Ke-Feng Dou; Kai-Shan Tao; Zhao-Xu Yang; A Joseph Tector; Burcin Ekser
Journal:  Transplantation       Date:  2016-10       Impact factor: 4.939

4.  Immunomodulatory effects of OX40Ig gene-modified adipose tissue-derived mesenchymal stem cells on rat kidney transplantation.

Authors:  Tao Liu; Yue Zhang; Zhongyang Shen; Xunfeng Zou; Xiaobo Chen; Li Chen; Yuliang Wang
Journal:  Int J Mol Med       Date:  2016-11-21       Impact factor: 4.101

5.  EP4 Antagonist-Elicited Extracellular Vesicles from Mesenchymal Stem Cells Rescue Cognition/Learning Deficiencies by Restoring Brain Cellular Functions.

Authors:  Shih-Yin Chen; Meng-Chieh Lin; Jia-Shiuan Tsai; Pei-Lin He; Wen-Ting Luo; Harvey Herschman; Hua-Jung Li
Journal:  Stem Cells Transl Med       Date:  2019-03-19       Impact factor: 6.940

Review 6.  Xenogeneic and Stem Cell-Based Therapy for Cardiovascular Diseases: Genetic Engineering of Porcine Cells and Their Applications in Heart Regeneration.

Authors:  Anne-Marie Galow; Tom Goldammer; Andreas Hoeflich
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

Review 7.  Translational Animal Models Provide Insight Into Mesenchymal Stromal Cell (MSC) Secretome Therapy.

Authors:  Rebecca M Harman; Charlotte Marx; Gerlinde R Van de Walle
Journal:  Front Cell Dev Biol       Date:  2021-03-19

Review 8.  MSC therapy in livestock models.

Authors:  Ellen M Harness; Nuradilla Binti Mohamad-Fauzi; James D Murray
Journal:  Transl Anim Sci       Date:  2022-01-27

Review 9.  Cardiac Xenotransplantation: Challenges, Evolution, and Advances.

Authors:  Jacinthe Boulet; Jonathan W Cunningham; Mandeep R Mehra
Journal:  JACC Basic Transl Sci       Date:  2022-06-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.